News & Updates
Filter by Specialty:
MV-140 vaccine proven safe, effective in recurrent UTI
Immunotherapy with MV-140 (Uromune) successfully prevents urinary tract infections (UTIs) in patients suffering from recurrent UTIs, suggest the results of a prospective study presented at the 38th Annual EAU Congress (EAU 2023).
MV-140 vaccine proven safe, effective in recurrent UTI
18 Apr 2023
NSAID use ups risk of heart failure in T2DM patients
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) tends to elevate the risk of first-time hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM), a study has shown. In addition, those with advanced age, elevated haemoglobin (Hb) A1c levels, and new users are particularly at higher risk.
NSAID use ups risk of heart failure in T2DM patients
17 Apr 2023
Investigational imaging agent holds promise for diagnosing renal cancer
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).
Investigational imaging agent holds promise for diagnosing renal cancer
17 Apr 2023
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan, used for heart failure, appears to have potent effects on 24‐hour blood pressure (BP) in Japanese patients with mild‐to‐moderate hypertension and in the subgroup of those with nondipping BP pattern, as shown in a study.
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
15 Apr 2023
Excessive air swallowing linked to dyspepsia, poor response to PPI therapy
Swallowing more air appears to induce both dyspepsia and refractoriness to typical symptoms of gastroesophageal reflux disease (GERD) to proton pump inhibitor (PPI) therapy, suggests a study.
Excessive air swallowing linked to dyspepsia, poor response to PPI therapy
14 Apr 2023
Topical NSAID treatment after selective laser trabeculoplasty of no benefit in glaucoma patients
The use of topical nonsteroidal anti-inflammatory drug (NSAID) does not seem to enhance the efficacy of selective laser trabeculoplasty for patients with glaucoma, as shown in a study.